Search
COPD_PatientSurvey_Infographic.pdf
world_patient_safety_day.pdf
Payments_to_patienten_organisations_2020.pdf
What is Pharmacovigilance & its role on Patient Safet.pdf
Stakeholders in Patient Safety & Pharmacovigilance.pdf
Patient advocacy tips for cancer
COPD Patient brochure
Payments_to_patienten_organisations_2022
Harold_and_Dorothy_Patient_Discussion_Guide_Factsheet_0.pdf
Effect_of_Tiotropium_and_Salmeterol_in_COPD_Patients_With .pdf
ischaemic_stroke_protection_as_treatment_priority_for_patients_with_atrial_fibrillation.pdf
PatientPoll_infographic_final.pdf
What is pharmacovigilance & its role on patient safety
What is being done for patient safety by different stakeholder
Biostatistics & Data Science
Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
SIRPα antagonist
SIRPα antagonist
Partnering Approach Video 2023
Our Animal Health Business Development & Licensing team talks about Boehringer Ingelheim’s unique partnering approach and spirit of collaboration.
Scleroderma Life Hacks
Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi
Spesolimab prevents GPP flares
Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
Translational Medicine & Clinical Pharmacology
We connect the right patient with the right drug on the right dosing schedule using data science methods from pharmacometrics to systems pharmacology.
What are acute exacerbations in IPF?
Risk factors for acute exacerbations in IPF are unclear, but there is evidence that a number of factors may increase risk. Learn more here.
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
U.S. FDA approves first treatment for generalized pustular psoriasis flares in adults
Boehringer Ingelheim announces the U.S. FDA has approved the first treatment for generalized pustular psoriasis (GPP) flares in adults
Pioneering for progress in generalized pustular psoriasis
An event, bringing together 170 delegates from across the world to strive for excellence in care of GPP